Perception of improved state of health and subjective quality of life in Crohn's disease patients treated with Infliximab

被引：4

作者：

Banovic, Ingrid ^{[1
]}

Gilibert, Daniel ^{[2
]}

Cosnes, Jacques ^{[3
]}

机构：

[1] Univ Bourgogne, Lab Ipse Paris 10 Nanterre, Pole AAFE, Equipe Ipse,Univ Nanterre P10,EA3984, F-21065 Dijon, France

[2] Univ Bourgogne, SPMS, F-21065 Dijon, France

[3] Univ Paris 06, CHU St Antoine, Serv Gastroenterol & Nutr, Paris VI, France

来源：

JOURNAL OF CROHNS & COLITIS | 2009年 / 3卷 / 01期

关键词：

Crohn's disease; Depressive mood; Activity of CD; Subjective quality of life; Infliximab; INFLAMMATORY-BOWEL-DISEASE; PSYCHOLOGICAL DISTRESS; DEPRESSION; IMPACT; VALIDATION; SAMPLE; MADRS;

D O I：

10.1016/j.crohns.2008.10.003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and aims and method: Although lnfliximab is a very potent therapy of refractory Crohn's disease, its administration requires iterative infusions in hospital and there are concerns regarding its long-term safety. The aim of this study was to assess in a sample of 51 patients suffering from CD the impact of type of treatment (intravenous Infliximab versus conventional therapy without Infliximab) on the evaluation of the state of health (CGI) and the quality of life (MOS-SF36). Secondary variables were also assessed: the impact of depression (MADRS), the impact of activity of the disease (Harvey-Bradshaw Index). Results: Overall, the assessments made using the CGI and the SF-36 revealed that the two types of treatment did not differ on the assessment of state of health and quality of life. A downward influence of depression and activity of the disease was observed. Conclusion: Patients considered more efficacy of Infliximab than its potential side effects. It seems important to assess and to consider depression in order to improve medical care setting of Crohn's disease. (c) 2008 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

引用

页码：25 / 31

页数：7

共 33 条

[1]

Blondel-Kucharski F, 2001, AM J GASTROENTEROL, V96, P2915

[2] Quality of life measurement in gastrointestinal and liver disorders [J].

Borgaonkar, MR ;

Irvine, EJ .

GUT, 2000, 47 (03) :444-454

[3] Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life [J].

Casellas, F ;

Vivancos, JL ;

Sampedro, M ;

Malagelada, JR .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (12) :2737-2742

[4] Impairment of health-related quality of life in patients with inflammatory bowel disease:: A Spanish multicenter study [J].

Casellas, F ;

Arenas, JI ;

Baudet, JS ;

Fábregas, S ;

García, N ;

Gelabert, J ;

Medina, C ;

Ochotorena, I ;

Papo, M ;

Rodrigo, L ;

Malagelada, JR .

INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) :488-496

[5] Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years [J].

Casellas, Francesc ;

Rodrigo, Luis ;

Nino, Pilar ;

Pantiga, Carmen ;

Riestra, Sabino ;

Malageloda, Juan-Ramon .

INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) :1395-1400

[6] Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience [J].

Cohen, RD .

INFLAMMATORY BOWEL DISEASES, 2001, 7 :S17-S22

[7]

Colombel JF, 1996, GASTROEN CLIN BIOL, V20, P1071

[8] Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery [J].

Cosnes, J ;

Nion-Larmurier, I ;

Beaugerie, L ;

Afchain, P ;

Tiret, E ;

Gendre, JP .

GUT, 2005, 54 (02) :237-241

[9] Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer [J].

Fallowfield, L ;

Atkins, L ;

Catt, S ;

Cox, A ;

Coxon, C ;

Langridge, C ;

Morris, R ;

Price, M .

ANNALS OF ONCOLOGY, 2006, 17 (02) :205-210

[10]

FELLEY C, 2008, REV MED SUISSE, V4, P206

← 1 2 3 4 →